TcL Pharma appoints French pharma veterans
pharmafile | April 1, 2011 | News story | Research and Development, Sales and Marketing | TcL, appointment, biotech, recruitment
TcL Pharma has appointed two seasoned veterans of the French pharmaceutical industry.
Dr Jean-Hugues Masgnaux joins the French biotech company as operations director and will also sit on its management committee, while Dr Didier Hoch has been appointed to its board.
Didier has 25 years’ experience in the pharmaceutical industry and between 2000 and 2010 ran Sanofi Pasteur MSD, a European joint venture vaccine between Sanofi-Aventis & Merck.
Prior to that he spent 15 years at Sanofi-Aventis forerunner Rhone Poulenc Rorer, serving as product manager, marketing director, deputy general manager and lastly VP for Africa & Middle-East.
Jean-Hugues began his career as an independent business development consultant at Innothera Laboratories & CNI, going on to become manager of licences and agreements at Servier and product manager for Fournier.
More recently he served as international project manager and marketing director for Grünenthal’s French subsidiary and was president of the Rottapharm/Madaus Group, before setting up a consulting business in 2009.
Nantes-based TcL focuses on the discovery and development of drugs to regulate the immune system in organ & tissue transplantation and autoimmune diseases.
The head of its board of directors Maryvonne Hiance said Didier and Jean-Hugues were joining the company at an important time as the firm starts looking to establish strategic relationships with industrial pharmaceutical partners.
“Didier Hoch’s experience in the pharmaceutical industry, particularly in the field of vaccines and biotechnology, as well as Jean Hugues Masgnaux’s know-how in the management of pharmaceutical companies in France and abroad will accelerate our development at a key time,” she said.
Dominic Tyer
Related Content
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
